Litre

Tom Oxley to Keynote 2024 Bioelectronic Medicine Forum in New York City

Retrieved on: 
Tuesday, March 19, 2024
General partnership, Patient, Beckman Coulter, Skin, MCRA, Litre, Mount Sinai Health System, Movement

NEW YORK, March 19, 2024 /PRNewswire/ -- Neurotech Reports , the publisher of the Neurotech Business Report and BioElectRx Business Report newsletters, announced that the Seventh Annual Bioelectronic Medicine Forum will take place on April 5, 2024.

Key Points: 
  • NEW YORK, March 19, 2024 /PRNewswire/ -- Neurotech Reports , the publisher of the Neurotech Business Report and BioElectRx Business Report newsletters, announced that the Seventh Annual Bioelectronic Medicine Forum will take place on April 5, 2024.
  • The keynote speaker at this year's event is Tom Oxley, CEO of Synchron and an interventional neurologist at Mount Sinai Health System.
  • For more information on the 2024 Bioelectronic Medicine Forum, contact Neurotech Reports at 415 546 1259 or visit this link: http://neurotechreports.com/pages/bioelectronic-medicine-forum.html .
  • Photo caption: Tom Oxley, Ph.D., M.D., will keynote the 2024 Bioelectronic Medicine Forum on April 5, 2024 in New York City.

Ceapro Provides Business Update on Progress of Ongoing Development Programs, Technology and Cosmeceutical Base Business

Retrieved on: 
Friday, February 23, 2024
Litre, Arrangement, Health Canada, OBG, TSX, Data monitoring committee, LDL, MBA, Assay, Safety, Cheese, University, Food engineering, University of Alberta, CZO, Infant, NPN, Journal, Protein, Clinical trial, Whey, Canada Business Corporations Act, Tissue, Water, Dietary supplement

EDMONTON, Alberta, Feb. 23, 2024 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), today provided an update on its progress across its current business.

Key Points: 
  • EDMONTON, Alberta, Feb. 23, 2024 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), today provided an update on its progress across its current business.
  • In addition to the proposed Arrangement, the Company continues to execute on progress across its ongoing development projects, as detailed below.
  • “We continue to make promising progress across all areas of our business.
  • Given the recent developments, we anticipate that all key success factors will align to expand our business model.

Dhai Dubai: Expo City Dubai launches stunning new 10-day festival of Emirati light art and culture

Retrieved on: 
Saturday, January 27, 2024
Elysian, Knowledge, Speech, Dubai Culture, Music, Photography, Dubai Design Week, Life, Emirates Fine Arts Society, Partnership, Electricity, Museum, Today, Creativity, Green, Litre, Emotion, Projection, Expo 2020, Light, Tourism

DUBAI, UAE, Jan. 27, 2024 /PRNewswire/ -- Dhai Dubai, the first-ever Emirati-led light art festival, has launched its illuminating 10-day programme at Expo City Dubai.

Key Points: 
  • DUBAI, UAE, Jan. 27, 2024 /PRNewswire/ -- Dhai Dubai, the first-ever Emirati-led light art festival, has launched its illuminating 10-day programme at Expo City Dubai.
  • The free-to-attend festival is created and organised by Expo City Dubai, in partnership with AGB Creative and supported by Dubai Culture and Arts Authority and will run from January 26 to February 4.
  • The attendees were taken into a mesmerizing journey of lights and music, stopping at each larger-than-life stunning light art installations by seven renowned Emirati artists and designers.
  • Amna Abulhoul, Executive Creative Director at Expo City Dubai, said: "Today, we add another bright light to our vibrant city.

Dhai Dubai: Expo City Dubai launches stunning new 10-day festival of Emirati light art and culture

Retrieved on: 
Saturday, January 27, 2024
Elysian, Knowledge, Speech, Dubai Culture, Music, Photography, Dubai Design Week, Life, Emirates Fine Arts Society, Partnership, Electricity, Museum, Today, Creativity, Green, Litre, Emotion, Projection, Expo 2020, Light, Tourism

DUBAI, UAE, Jan. 27, 2024 /PRNewswire/ -- Dhai Dubai, the first-ever Emirati-led light art festival, has launched its illuminating 10-day programme at Expo City Dubai.

Key Points: 
  • DUBAI, UAE, Jan. 27, 2024 /PRNewswire/ -- Dhai Dubai, the first-ever Emirati-led light art festival, has launched its illuminating 10-day programme at Expo City Dubai.
  • The free-to-attend festival is created and organised by Expo City Dubai, in partnership with AGB Creative and supported by Dubai Culture and Arts Authority and will run from January 26 to February 4.
  • The attendees were taken into a mesmerizing journey of lights and music, stopping at each larger-than-life stunning light art installations by seven renowned Emirati artists and designers.
  • Amna Abulhoul, Executive Creative Director at Expo City Dubai, said: "Today, we add another bright light to our vibrant city.

Pathway to Cures Announces Inaugural Fund Update

Retrieved on: 
Thursday, November 2, 2023
General Health, Fund Raising, Health, Foundation, Philanthropy, Knowledge, Von Willebrand disease, Organizational founder, VWD, Hope, Biotechnology, MD, Doctor of Philosophy, MBA, Research, Hemostasis, Tan, Science, Blood, Heavy menstrual bleeding, Woman, Investment, Desmopressin, Litre, Parent, Pharmaceutical industry, Management, Pathway

Pathway to Cures (P2C) held its inaugural fund meeting on Saturday, October 28th in Chicago, Illinois.

Key Points: 
  • Pathway to Cures (P2C) held its inaugural fund meeting on Saturday, October 28th in Chicago, Illinois.
  • Pathway to Cures, an affiliate of the National Bleeding Disorders Foundation (NBDF), is a venture philanthropy fund focused on investing in early-stage companies developing cures, therapies, or enabling technologies in support of the inheritable blood and bleeding disorders community.
  • “Transcutaneous auricular neurostimulation (tAN) is a non-invasive method demonstrating great promise for treating various diseases.
  • “We have reviewed 114 companies over the past few months, whose promising research will accelerate the treatments and cures for rare diseases in the years to come.

Global UHT Milk Industry Report 2023: Market Trends, Share, Size, Growth, Opportunities and Forecasts 2022-2028 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, October 18, 2023
Food, Beverage, Retail, Government, Urbanization, Litre, Developed country, Milk, COVID-19, Mineral, Restaurant, Travel, Process control block, Investment, Supermarket, Tea, UHT, Growth

The "UHT Milk Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "UHT Milk Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028" report has been added to ResearchAndMarkets.com's offering.
  • Furthermore, awareness of the benefits of UHT milk over conventional milk is increasing due to marketing initiatives through various channels.
  • What is the breakup of the global UHT milk market based on the distribution channel?
  • What are the key regions in the global UHT milk market?

Pathway to Cures Announces Venture Investment in Five Liters

Retrieved on: 
Monday, October 16, 2023
Research, General Health, Pharmaceutical, Philanthropy, Fund Raising, Foundation, Clinical Trials, Science, Biotechnology, Other Philanthropy, Other Science, Health, VNS, MBA, Doctor of Philosophy, Litre, Indian Council of Medical Research, Bleeding, Anemia, Sickle cell disease, MD, Northwell Health, Injury, Von Willebrand disease, VWD, Electricity, Vagus nerve stimulation, Medical research, Desmopressin, Feinstein Institutes for Medical Research, Coagulopathy, Haemophilia, Scientific Advisory Group, Tan, Hemostasis, Nature Communications, Cyclic permutation, Blood, Vagus nerve, Patient, Pharmaceutical industry, Medical device, The New York Times, Cure, Pathway

Pathway to Cures (P2C) announced today its investment of $500,000 in Five Liters, a subsidiary of Spark Biomedical, to develop therapies for treating inheritable blood and bleeding disorders.

Key Points: 
  • Pathway to Cures (P2C) announced today its investment of $500,000 in Five Liters, a subsidiary of Spark Biomedical, to develop therapies for treating inheritable blood and bleeding disorders.
  • Pathway to Cures, an affiliate of the National Bleeding Disorders Foundation, is a venture philanthropy fund focused on early-stage companies developing cures, therapies, or enabling technologies in support of the inheritable blood and bleeding disorders community.
  • This significant milestone is made possible through Five Liters' collaboration with Northwell Health’s Feinstein Institutes for Medical Research in New York.
  • Dr. Recht is Chief Medical and Scientific Officer at both Pathway to Cures and the National Bleeding Disorders Foundation (NBDF) and chairs the Pathway to Cures Scientific Advisory Group.

New Brochure on Piezo Transducers for Microfluidics, from PI

Retrieved on: 
Wednesday, August 30, 2023
Litre, Transducer, Electronics

AUBURN, Mass., Aug. 30, 2023 /PRNewswire-PRWeb/ -- Piezoelectric microfluidic devices are used for dispensing and controlling miniscule volumes down to the nanoliter and picoliter range. These piezo transducers enable liquid handling applications in the field of lab automation and vitro diagnostics.

Key Points: 
  • Our piezo components address your challenge of liquid handling in a small space.
  • AUBURN, Mass., Aug. 30, 2023 /PRNewswire-PRWeb/ -- Piezoelectric microfluidic devices are used for dispensing and controlling miniscule volumes down to the nanoliter and picoliter range.
  • These piezo transducers enable liquid handling applications in the field of lab automation and vitro diagnostics.

Ceapro Inc. Reports 2023 Second Quarter and Six-Month Financial Results and Provides Corporate Update

Retrieved on: 
Tuesday, August 29, 2023
The Angiogenesis Foundation, Senior, Litre, Urine, Symrise, Clinical trial, MBA, Coenzyme Q10, Regulation and licensure in engineering, Trial of the century, YBG, Special Operations Executive, Regeneration, American Thoracic Society, McMaster University, Blood, Pharmacy, Growth, AVS, Dubai Health Authority, CZO, Safety, Wound healing, Pharmaceutical industry, Management, Dietary supplement, Medical device, Ready-mix concrete, Fine chemical, Cryptocurrency

EDMONTON, Alberta, Aug. 29, 2023 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced financial results and operational highlights for the second quarter and six months ended June 30, 2023.

Key Points: 
  • Further, over the past quarter we remained very active with our activities related to strategic corporate initiatives.
  • Stability studies are ongoing for the 30mg and 240mg pills formulation manufactured, packaged and labeled by Corealis Inc. GMP Manufacturing Services.
  • Studies showed statistically significant results characterizing the bioactivity of both Ceapro’s oat-derived bioactive products on wound healing and tissue regeneration.
  • Financial Highlights for the Second Quarter and the Six-Month Period Ended June 30, 2022
    Sales of $1,869,000 for the second quarter of 2023 and $5,364,000 for the first six months of 2023 compared to $5,500,000 and $11,672,000 for the comparative periods in 2022.

Five Liters sets clinical sights on novel bioelectric treatment for von Willebrand Disease

Retrieved on: 
Thursday, July 6, 2023
VNS, Male, Von Willebrand disease, Partnership, Depression, Bleeding, Nature, Litre, VWD, Urine, Feinstein Institutes for Medical Research, Tan, Anxiety, Anovulatory cycle, Clinical trial, Nature Communications, Haemophilia, Vagus nerve stimulation, Research, Northwell Health, Desmopressin, Cyclic permutation, Bruise, Blood, Feinstein, Mouse, Hematoma, Medical research, FDA, Mental health, Injury, Medical device, Birth control

Five Liters, a subsidiary of Spark Biomedical, is dedicated to exploring the hemostatic effects of vagus nerve stimulation (VNS), specifically transcutaneous auricular neurostimulation (tAN).

Key Points: 
  • Five Liters, a subsidiary of Spark Biomedical, is dedicated to exploring the hemostatic effects of vagus nerve stimulation (VNS), specifically transcutaneous auricular neurostimulation (tAN).
  • Dr. Navid Khodaparast, Chief Science Officer of Spark and Five Liters stated “Von Willebrand Disease is an inherited bleeding disorder in which blood does not clot properly, leading to bleeding events and joint problems.
  • At Five Liters, our primary clinical initiative is to demonstrate that tAN therapy can safely alleviate menorrhagia in females with VWD.
  • Thanks to this partnership and the Nature article, Five Liters is thrilled to move forward with its mission.